Report cover image

Global Multivalent Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 02, 2025
Length 199 Pages
SKU # APRC20106411

Description

Summary

According to APO Research, The global Multivalent Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Multivalent Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Multivalent Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Multivalent Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Multivalent Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Multivalent Vaccines include Bavarian Nordic (Denmark), CSL Limited (Australia), Daiichi Sankyo (Japan), Emergent BioSolutions, Inc(US), GlaxoSmithKline, plc (U.K.), MedImmune, LLC (US), Mitsubishi Tanabe Pharma Corporation (Japan), Panacea Biotec (India) and Protein Sciences Corporation (US), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Multivalent Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Multivalent Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Multivalent Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multivalent Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Multivalent Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Multivalent Vaccines sales, projected growth trends, production technology, application and end-user industry.


Multivalent Vaccines Segment by Company

Bavarian Nordic (Denmark)
CSL Limited (Australia)
Daiichi Sankyo (Japan)
Emergent BioSolutions, Inc(US)
GlaxoSmithKline, plc (U.K.)
MedImmune, LLC (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Panacea Biotec (India)
Protein Sciences Corporation (US)
Serum Institute of India Pvt. Ltd. (India)
Astellas Pharma Inc. (Japan)
Pfizer, Inc(US)
Merck & Co., Inc(US)
Johnson & Johnson (US)
Sanofi Pasteur SA (France)

Multivalent Vaccines Segment by Type

Toxoid Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated and Subunit Vaccines
Recombinant Vaccines

Multivalent Vaccines Segment by Application

Pediatrics
Adults

Multivalent Vaccines Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multivalent Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multivalent Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Multivalent Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Multivalent Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Multivalent Vaccines Market Size, 2020 VS 2024 VS 2031
1.3 Global Multivalent Vaccines Market Size Estimates and Forecasts (2020-2031)
1.4 Global Multivalent Vaccines Sales Estimates and Forecasts (2020-2031)
1.5 Global Multivalent Vaccines Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Multivalent Vaccines Market Dynamics
2.1 Multivalent Vaccines Industry Trends
2.2 Multivalent Vaccines Industry Drivers
2.3 Multivalent Vaccines Industry Opportunities and Challenges
2.4 Multivalent Vaccines Industry Restraints
3 Multivalent Vaccines Market by Manufacturers
3.1 Global Multivalent Vaccines Revenue by Manufacturers (2020-2025)
3.2 Global Multivalent Vaccines Sales by Manufacturers (2020-2025)
3.3 Global Multivalent Vaccines Average Sales Price by Manufacturers (2020-2025)
3.4 Global Multivalent Vaccines Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Multivalent Vaccines Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Multivalent Vaccines Manufacturers, Product Type & Application
3.7 Global Multivalent Vaccines Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Multivalent Vaccines Market CR5 and HHI
3.8.2 Global Top 5 and 10 Multivalent Vaccines Players Market Share by Revenue in 2024
3.8.3 2024 Multivalent Vaccines Tier 1, Tier 2, and Tier 3
4 Multivalent Vaccines Market by Type
4.1 Multivalent Vaccines Type Introduction
4.1.1 Toxoid Vaccines
4.1.2 Live Attenuated Vaccines
4.1.3 Conjugate Vaccines
4.1.4 Inactivated and Subunit Vaccines
4.1.5 Recombinant Vaccines
4.2 Global Multivalent Vaccines Sales by Type
4.2.1 Global Multivalent Vaccines Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Multivalent Vaccines Sales by Type (2020-2031)
4.2.3 Global Multivalent Vaccines Sales Market Share by Type (2020-2031)
4.3 Global Multivalent Vaccines Revenue by Type
4.3.1 Global Multivalent Vaccines Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Multivalent Vaccines Revenue by Type (2020-2031)
4.3.3 Global Multivalent Vaccines Revenue Market Share by Type (2020-2031)
5 Multivalent Vaccines Market by Application
5.1 Multivalent Vaccines Application Introduction
5.1.1 Pediatrics
5.1.2 Adults
5.2 Global Multivalent Vaccines Sales by Application
5.2.1 Global Multivalent Vaccines Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Multivalent Vaccines Sales by Application (2020-2031)
5.2.3 Global Multivalent Vaccines Sales Market Share by Application (2020-2031)
5.3 Global Multivalent Vaccines Revenue by Application
5.3.1 Global Multivalent Vaccines Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Multivalent Vaccines Revenue by Application (2020-2031)
5.3.3 Global Multivalent Vaccines Revenue Market Share by Application (2020-2031)
6 Global Multivalent Vaccines Sales by Region
6.1 Global Multivalent Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Multivalent Vaccines Sales by Region (2020-2031)
6.2.1 Global Multivalent Vaccines Sales by Region (2020-2025)
6.2.2 Global Multivalent Vaccines Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Multivalent Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Multivalent Vaccines Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Multivalent Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Multivalent Vaccines Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Multivalent Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Multivalent Vaccines Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Multivalent Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Multivalent Vaccines Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Multivalent Vaccines Revenue by Region
7.1 Global Multivalent Vaccines Revenue by Region
7.1.1 Global Multivalent Vaccines Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Multivalent Vaccines Revenue by Region (2020-2025)
7.1.3 Global Multivalent Vaccines Revenue by Region (2026-2031)
7.1.4 Global Multivalent Vaccines Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Multivalent Vaccines Revenue (2020-2031)
7.2.2 North America Multivalent Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Multivalent Vaccines Revenue (2020-2031)
7.3.2 Europe Multivalent Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Multivalent Vaccines Revenue (2020-2031)
7.4.2 Asia-Pacific Multivalent Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Multivalent Vaccines Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Multivalent Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Bavarian Nordic (Denmark)
8.1.1 Bavarian Nordic (Denmark) Comapny Information
8.1.2 Bavarian Nordic (Denmark) Business Overview
8.1.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Bavarian Nordic (Denmark) Multivalent Vaccines Product Portfolio
8.1.5 Bavarian Nordic (Denmark) Recent Developments
8.2 CSL Limited (Australia)
8.2.1 CSL Limited (Australia) Comapny Information
8.2.2 CSL Limited (Australia) Business Overview
8.2.3 CSL Limited (Australia) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 CSL Limited (Australia) Multivalent Vaccines Product Portfolio
8.2.5 CSL Limited (Australia) Recent Developments
8.3 Daiichi Sankyo (Japan)
8.3.1 Daiichi Sankyo (Japan) Comapny Information
8.3.2 Daiichi Sankyo (Japan) Business Overview
8.3.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Daiichi Sankyo (Japan) Multivalent Vaccines Product Portfolio
8.3.5 Daiichi Sankyo (Japan) Recent Developments
8.4 Emergent BioSolutions, Inc(US)
8.4.1 Emergent BioSolutions, Inc(US) Comapny Information
8.4.2 Emergent BioSolutions, Inc(US) Business Overview
8.4.3 Emergent BioSolutions, Inc(US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Emergent BioSolutions, Inc(US) Multivalent Vaccines Product Portfolio
8.4.5 Emergent BioSolutions, Inc(US) Recent Developments
8.5 GlaxoSmithKline, plc (U.K.)
8.5.1 GlaxoSmithKline, plc (U.K.) Comapny Information
8.5.2 GlaxoSmithKline, plc (U.K.) Business Overview
8.5.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Portfolio
8.5.5 GlaxoSmithKline, plc (U.K.) Recent Developments
8.6 MedImmune, LLC (US)
8.6.1 MedImmune, LLC (US) Comapny Information
8.6.2 MedImmune, LLC (US) Business Overview
8.6.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 MedImmune, LLC (US) Multivalent Vaccines Product Portfolio
8.6.5 MedImmune, LLC (US) Recent Developments
8.7 Mitsubishi Tanabe Pharma Corporation (Japan)
8.7.1 Mitsubishi Tanabe Pharma Corporation (Japan) Comapny Information
8.7.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
8.7.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Portfolio
8.7.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Developments
8.8 Panacea Biotec (India)
8.8.1 Panacea Biotec (India) Comapny Information
8.8.2 Panacea Biotec (India) Business Overview
8.8.3 Panacea Biotec (India) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Panacea Biotec (India) Multivalent Vaccines Product Portfolio
8.8.5 Panacea Biotec (India) Recent Developments
8.9 Protein Sciences Corporation (US)
8.9.1 Protein Sciences Corporation (US) Comapny Information
8.9.2 Protein Sciences Corporation (US) Business Overview
8.9.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Protein Sciences Corporation (US) Multivalent Vaccines Product Portfolio
8.9.5 Protein Sciences Corporation (US) Recent Developments
8.10 Serum Institute of India Pvt. Ltd. (India)
8.10.1 Serum Institute of India Pvt. Ltd. (India) Comapny Information
8.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
8.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Portfolio
8.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Developments
8.11 Astellas Pharma Inc. (Japan)
8.11.1 Astellas Pharma Inc. (Japan) Comapny Information
8.11.2 Astellas Pharma Inc. (Japan) Business Overview
8.11.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Portfolio
8.11.5 Astellas Pharma Inc. (Japan) Recent Developments
8.12 Pfizer, Inc(US)
8.12.1 Pfizer, Inc(US) Comapny Information
8.12.2 Pfizer, Inc(US) Business Overview
8.12.3 Pfizer, Inc(US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Pfizer, Inc(US) Multivalent Vaccines Product Portfolio
8.12.5 Pfizer, Inc(US) Recent Developments
8.13 Merck & Co., Inc(US)
8.13.1 Merck & Co., Inc(US) Comapny Information
8.13.2 Merck & Co., Inc(US) Business Overview
8.13.3 Merck & Co., Inc(US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Merck & Co., Inc(US) Multivalent Vaccines Product Portfolio
8.13.5 Merck & Co., Inc(US) Recent Developments
8.14 Johnson & Johnson (US)
8.14.1 Johnson & Johnson (US) Comapny Information
8.14.2 Johnson & Johnson (US) Business Overview
8.14.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Johnson & Johnson (US) Multivalent Vaccines Product Portfolio
8.14.5 Johnson & Johnson (US) Recent Developments
8.15 Sanofi Pasteur SA (France)
8.15.1 Sanofi Pasteur SA (France) Comapny Information
8.15.2 Sanofi Pasteur SA (France) Business Overview
8.15.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Sanofi Pasteur SA (France) Multivalent Vaccines Product Portfolio
8.15.5 Sanofi Pasteur SA (France) Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Multivalent Vaccines Value Chain Analysis
9.1.1 Multivalent Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Multivalent Vaccines Production Mode & Process
9.2 Multivalent Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Multivalent Vaccines Distributors
9.2.3 Multivalent Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.